GLP-1 receptor agonist: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) Backfill inline <ref> citations per new sitewide citation rule |
MDElliottMD (talk | contribs) Sweep: "indications" -> "problems" sitewide terminology update (preserves MedTemplate param name) |
||
| Line 35: | Line 35: | ||
|} | |} | ||
== | == Problems == | ||
* '''Type 2 diabetes mellitus''' — first- or second-line per [[ADA Standards of Care|ADA 2025 Standards of Care]],<ref name="ada2025">American Diabetes Association. ''Standards of Care in Diabetes — 2025.'' ''Diabetes Care'' 48(Suppl. 1):S1–S352. doi:10.2337/dc25-S001</ref> especially when [[ASCVD]], [[heart failure]], [[CKD]], or obesity is co-present | * '''Type 2 diabetes mellitus''' — first- or second-line per [[ADA Standards of Care|ADA 2025 Standards of Care]],<ref name="ada2025">American Diabetes Association. ''Standards of Care in Diabetes — 2025.'' ''Diabetes Care'' 48(Suppl. 1):S1–S352. doi:10.2337/dc25-S001</ref> especially when [[ASCVD]], [[heart failure]], [[CKD]], or obesity is co-present | ||